Understand the source comparison
Erectile Dysfunction Peptides 2026 Update: Efficacy Comparison
PT-141 (bremelanotide) Melanocortin MC3/MC4 receptor agonist. Hypothalamic arousal signaling 45–90 minutes (on-demand dosing) 54.5% responder rate (≥4-point IIEF increase) vs 34% placebo Single-dose effect lasts 6–12 hours ED with intact vascular function but
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- PT-141 (bremelanotide)
- Melanocortin MC3/MC4 receptor agonist. Hypothalamic arousal signaling
- 45–90 minutes (on-demand dosing)
- 54.5% responder rate (≥4-point IIEF increase) vs 34% placebo
- Single-dose effect lasts 6–12 hours
- ED with intact vascular function but poor arousal initiation; PDE5 inhibitor non-responders
- Gonadorelin (GnRH analog)
- Pituitary LH/FSH release → endogenous testosterone production
- 8–12 weeks (chronic twice-weekly dosing)
- 52% subjective erectile improvement in secondary hypogonadism cohort (open-label)
- Sustained with continued dosing; declines 4–8 weeks after discontinuation
- ED secondary to hypogonadism with preserved pituitary-gonadal axis; fertility preservation
- Tadalafil (PDE5 inhibitor, reference)
- Prevents cGMP breakdown in penile smooth muscle → vasodilation
- 30–60 minutes (on-demand); 3–5 days (daily low-dose)
- 71% responder rate (≥4-point IIEF increase) vs 28% placebo
- Single-dose effect lasts 24–36 hours; daily dosing maintains baseline
- First-line ED treatment; vascular insufficiency; BPH co-management
- Combination PT-141 + tadalafil
- Central arousal + peripheral vasodilation
- 45–90 minutes
- 8.2-point mean IIEF improvement vs 5.1 monotherapy (pilot data, n=42)
- Under investigation
- Refractory moderate ED; combined arousal and vascular insufficiency